The Dutch Pulmonary Hypertension Association has contributed financially to the RECOMPENSE Phase 4 study on sotatercept conducted by the Amsterdam University Medical Center

The Dutch Pulmonary Hypertension Association, Stichting Pulmonale Hypertensie, has contributed financially with an amount of € 40.000 the RECOMPENSE – Right VEntricular COMPENsation with SotatercEpt – Phase 4 study conducted by the Amsterdam UMC. This research aims to investigate sotatercept’s effects on right ventricular function. Background Several large international studies have already been conducted in […]

The Dutch Pulmonary Hypertension Association has contributed financially to the RECOMPENSE Phase 4 study on sotatercept conducted by the Amsterdam University Medical Center Read Post »

Novel PET approach may help to identify early signs of pulmonary arterial hypertension, Journal of Nuclear Medicine, January 2025

A new molecular imaging technique called18F-FAPI Positron Emission Tomography (PET) has been shown to be able to detect the first signs of the tissue remodeling typical of patients with pulmonary arterial hypertension and could provide physicians with an early marker for disease progression. This approach has the potential to pave the way for more personalized

Novel PET approach may help to identify early signs of pulmonary arterial hypertension, Journal of Nuclear Medicine, January 2025 Read Post »

Prognostic relevance of exercise pulmonary hypertension: results of the multicentre PEX-NET Clinical Research Collaboration, European Respiratory Journal

The PEX-NET (Pulmonary Haemodynamics during Exercise Network) registry enrolled patients who underwent clinically indicated right heart catheterisations both at rest and ergometer exercise from 23 PH centres worldwide. The aim of the study was to explore the prognostic relevance of exercise haemodynamics and its added value to resting haemodynamics are missing. The study finds that

Prognostic relevance of exercise pulmonary hypertension: results of the multicentre PEX-NET Clinical Research Collaboration, European Respiratory Journal Read Post »

From basic scientific research to the development of new drugs for pulmonary arterial hypertension: insights from activin-targeting agents, Breathe, January 21, 2025

This article, authored by Prof. Christophe Guignabert, Director of Research at Inserm – Université Paris-Saclay, France, explores the pathophysiology of pulmonary arterial hypertension, focusing on key mechanisms of disease progression. It notes that in the past three decades, significant advancements in treatment, with 12 new drugs, have improved patients’ quality of life, reduced short-term mortality

From basic scientific research to the development of new drugs for pulmonary arterial hypertension: insights from activin-targeting agents, Breathe, January 21, 2025 Read Post »

Simulation of clinical trials of oral treprostinil in pulmonary arterial hypertension using a virtual population, Nature Briefing Journal, January 15, 2025

The study published recently in the Nature Briefing Journal explores using mathematical modeling to address drug development challenges in pulmonary arterial hypertension. Researchers developed a quantitative systems pharmacology (QSP) model in the context of oral treprostinil clinical studies to predict changes in pulmonary vascular resistance and six-minute walk distance by creating a virtual patient population

Simulation of clinical trials of oral treprostinil in pulmonary arterial hypertension using a virtual population, Nature Briefing Journal, January 15, 2025 Read Post »

Only a minority of US patients receive pulmonary arterial hypertension-specific prescriptions from a pulmonary hypertension center, reveal the findings of a recent study

The authors of this article, published on the American Journal of Respiratory and Critical Care Medicine on January 13, 2025 say that guidelines recommend patients with pulmonary arterial hypertension be referred to pulmonary hypertension centers, but little is known about where care is actually delivered in the United States. Prescription patterns were used to estimate

Only a minority of US patients receive pulmonary arterial hypertension-specific prescriptions from a pulmonary hypertension center, reveal the findings of a recent study Read Post »

Pathway to care, treatment and disease burden of pulmonary arterial hypertension: a real-world survey of physicians and patients in Latin America, British Medical Journal, December 31, 2024

An article published on the British Medical Journal Open on December 31, 2024, titled “Pathway to care, treatment and disease burden of pulmonary arterial hypertension: a real-world survey of physicians and patients in Latin America”, reports on the findings of a cross-sectional survey with retrospective data collection. A total of 246 physicians, from University/teaching hospitals,

Pathway to care, treatment and disease burden of pulmonary arterial hypertension: a real-world survey of physicians and patients in Latin America, British Medical Journal, December 31, 2024 Read Post »

Stronger Together: Celebrating the Pulmonary Hypertension Community’s 2024 Milestones

The year 2024 has seen significant progress in the fight against pulmonary hypertension, marked by critical milestones across research, clinical care, advocacy, awareness, and patient engagement, with an unprecedented level of patient involvement in scientific discourse. As we head into 2025 with all that has been achieved we are well positioned in furthering our mission!

Stronger Together: Celebrating the Pulmonary Hypertension Community’s 2024 Milestones Read Post »

Challenges in implementing the new European clinical guidelines in Central and Eastern Europe: a review from the Polish Heart Journal 

An article published in the Polish Heart Journal on December 23, 2024, titled “Emerging therapies and new directions in the treatment of pulmonary arterial hypertension” points out that the integration of novel therapeutic protocols into everyday medical practice faces various obstacles, particularly when considering regional differences in implementation. The paper draws insights from medical experts

Challenges in implementing the new European clinical guidelines in Central and Eastern Europe: a review from the Polish Heart Journal  Read Post »

Proud to celebrate the 14 live webinars we have organised since the series launched in June 2023! A huge thank you to all our speakers and participants!

The Alliance for Pulmonary Hypertension (AfPH) recently concluded its 14th webinar, marking the culmination of an educational initiative that began in June 2023. These virtual gatherings brought together internationally renowned experts in pulmonary hypertension, who shared their expertise on a comprehensive range of topics crucial to advancing patient care and quality of life. The diverse

Proud to celebrate the 14 live webinars we have organised since the series launched in June 2023! A huge thank you to all our speakers and participants! Read Post »

Update on the Pulmonary Vascular Research Institute (PVRI)’s Pulmonary Hypertension Global Survey (PH GPS)

Almost 4,000 patients and carers across 85 countries completed Phase 1 of the Pulmonary Hypertension Global Patient Survey (PH GPS). The survey was translated into 24 languages and launched in October 2023. The survey was written by a multidisciplinary panel of pulmonary hypertension specialists and patient group advocates from the pulmonary hypertension associations of Europe,

Update on the Pulmonary Vascular Research Institute (PVRI)’s Pulmonary Hypertension Global Survey (PH GPS) Read Post »

Special issue of “Transplant International” addresses race, gender, socioeconomic and geographic disparities in transplantation

Transplant International has published a special issue of its journal on “Diversity, Equity, and Inclusion in Transplantation”. This issue presents a collection of studies that examine inequities in transplantation related to race, gender, socioeconomics, and geography, providing evidence and insights into these persistent disparities. Download the pdf of the special issue of Transplant International at

Special issue of “Transplant International” addresses race, gender, socioeconomic and geographic disparities in transplantation Read Post »

AI Model for Depression Diagnosis Developed in Finland: A Potential Breakthrough for Accessible and Early Mental Health Care

Researchers at Kaunas University of Technology, Finland, have developed an artificial intelligence model that combines speech and brain activity data to diagnose depression with an accuracy of 97.53 percent. This innovative approach, detailed in an article for Brain Sciences dated October 15, 2024, leverages both electroencephalogram signals and voice recordings to assess emotional states more

AI Model for Depression Diagnosis Developed in Finland: A Potential Breakthrough for Accessible and Early Mental Health Care Read Post »

Effective Communication Key to Improving Medication Adherence in Pulmonary Arterial Hypertension, findings of the PERSIST Study, Pulmonary Circulation

A recent study published in Pulmonary Circulation highlights the vital role of proactive communication in improving medication persistence among individuals with pulmonary arterial hypertension. The study, titled PERSIST (Practices affEcting macitentan and selexipag patient persistence Rates utilizing pulmonary arterial hypertension clinical Site and patIent perSpecTives), surveyed 134 patients and 23 healthcare professionals across the United

Effective Communication Key to Improving Medication Adherence in Pulmonary Arterial Hypertension, findings of the PERSIST Study, Pulmonary Circulation Read Post »

Appraisal and evaluation of quality of life in pulmonary arterial hypertension instruments: A systematic review, Respiratory Medicine, November/December 2024

This systematic review, published on the Respiratory Medicine November-December 2024 issue, focuses on identifying and evaluating quality of life (QoL) measurement instruments specifically designed for patients with pulmonary arterial hypertension (PAH): EmPHasis-10, CAMPHOR, PAH SYMPACT, and LPHQ. Using the 2018 COSMIN guidelines, the researchers searched multiple medical databases to assess these instruments’ psychometric properties. While

Appraisal and evaluation of quality of life in pulmonary arterial hypertension instruments: A systematic review, Respiratory Medicine, November/December 2024 Read Post »

Efficacy and Safety of Sotatercept Across Ranges of Cardiac Index in Patients with Pulmonary Arterial Hypertension, Journal of Heart and Lung Transplantation, December 5, 2024

Pooled data from the PULSAR and STELLAR trials were used for this study, published on December 5, 2024 on the The Journal of Heart and Lung Transplantation, which compared effects of the activin signaling inhibitor sotatercept (Winrevair) across pulmonary arterial hypertension (PAH) subgroups stratified by baseline cardiac index (CI). The analysis evaluated 429 participants divided

Efficacy and Safety of Sotatercept Across Ranges of Cardiac Index in Patients with Pulmonary Arterial Hypertension, Journal of Heart and Lung Transplantation, December 5, 2024 Read Post »

Poor sleep quality should not be overlooked in pulmonary arterial hypertension patient as it represents an additional disease burden, Acta Cardiologica

“Poor sleep quality is an overlooked symptom in patients with pulmonary arterial hypertension (PAH), however it may significantly contribute to disease burden”, claim the authors of a study titled “Sleep Quality and Its Predictors among Dyspnea, Fatigue and Exercise Capacity in Pulmonary Arterial Hypertension”, published in Acta Cardiologica. Karen Jacobson-Sive has summarised the key takeaways

Poor sleep quality should not be overlooked in pulmonary arterial hypertension patient as it represents an additional disease burden, Acta Cardiologica Read Post »

Challenges associated with non-oral pulmonary arterial hypertension treatments, Aldo Aguirre-Camacho, Therapeutic Advances in Respiratory Disease

A study titled “Patients’ perspectives on the challenges associated with receiving non-oral pulmonary arterial hypertension treatment: a mixed methods study”, by Aldo Aguirre-Camacho, was published on “Therapeutic Advances in Respiratory Disease” on November 21, 2024. The study investigates how non-oral treatments for pulmonary arterial hypertension impact patients’ quality of life beyond the challenges posed by

Challenges associated with non-oral pulmonary arterial hypertension treatments, Aldo Aguirre-Camacho, Therapeutic Advances in Respiratory Disease Read Post »

National Dutch Pulmonary Hypertension Information Day: A Blend of Education, Connection, and Hope

On Saturday, November 23, 2024, the Dutch National Pulmonary Hypertension Information Day brought together patients, caregivers, and medical professionals for an inspiring and informative symposium. This annual event, designed specifically for pulmonary hypertension patients and their loved ones, offered a full day of learning, connection, and support. The event was expertly chaired by Dr. Sanne

National Dutch Pulmonary Hypertension Information Day: A Blend of Education, Connection, and Hope Read Post »

Starting today, December 6, 2024, the International Symposium on Pulmonary Hypertension and 9th Meeting of the Latin American Leaders, Miraflores, Peru

The Sociedad Latina de Hipertensión Pulmonar SLHP, the Colegio Médico del Perú Región Lima and the pulmonary hypertension patient association “Llapan Kallpa”, are inviting to the ,The International Symposium on Pulmonary Hypertension and the 9th meeting of Latin American leaders being held on 6-7 December, with the participation of esteemed professionals including Dr. Pilar Escribano,

Starting today, December 6, 2024, the International Symposium on Pulmonary Hypertension and 9th Meeting of the Latin American Leaders, Miraflores, Peru Read Post »

TRANSLATE »
Scroll to Top